Study wrapper · #334
Expression of Concern: Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study.
Editor's note
No abstract accompanies this record because it is not a study but an Expression of Concern — a formal notice from The Journal of Urology flagging integrity questions about the 2008 randomized trial by Safarinejad and Hosseini, which reported that bremelanotide improved erectile function in men who had not responded to sildenafil. This matters directly: that trial is a load-bearing piece of the already-thin human evidence for bremelanotide in male sexual dysfunction, a use that was never carried to a Phase III programme. An Expression of Concern does not by itself retract or disprove the findings, but it signals that a journal has credible reason to doubt the work's reliability and that readers should treat its conclusions with caution pending resolution. The practical effect is to further weaken an off-label evidence base that was never strong. Weight the underlying male-ED claim more skeptically as a result; the female-HSDD approval, which rests on separate Phase III trials, is unaffected by this notice.
Plain-language abstract
This record has no abstract because it is not a research study — it is an "Expression of Concern," a formal notice published by a medical journal to warn readers that questions have been raised about the reliability of a previously published paper. The paper in question is a 2008 randomized, double-blind, placebo-controlled trial reporting that bremelanotide helped restore erectile function in men who had not responded to sildenafil (Viagra). An Expression of Concern does not automatically mean the study was wrong or has been withdrawn, but it does mean the journal has enough reason for doubt that readers should be cautious about trusting its results until the matter is resolved. This is significant because that trial is one of the few human studies supporting the idea of using bremelanotide for erectile dysfunction in men — a use it is not approved for. The notice therefore weakens already-limited evidence for that off-label use. It does not affect the separate, later trials that supported the drug's approval for low sexual desire in women.